D
espite the immense impact of periprosthetic joint infection (PJI) on patients and society, its diagnosis remains imperfect and often very challenging 1 . Currently, an absolute test for the diagnosis of PJI does not exist, compelling clinicians to rely on a combination of synovial fluid tests and serological markers 2 . Because of the lack of an absolute test, the Musculoskeletal Infection Society (MSIS) introduced a set of diagnostic criteria for PJI that were recently modified by the International Consensus Meeting (ICM) on Periprosthetic Joint Infection 3 . The guidelines include major and minor diagnostic criteria, with the latter involving measurements of serum C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR), synovial fluid white blood-cell (WBC) count and neutrophil differential, culture, and leukocyte esterase testing (Table I) . Although numerous serological markers for PJI have been evaluated in the past, including interleukin 6 (IL-6) and others 1 , the most widely used serological tests for the diagnosis of PJI are the assessment of ESR and CRP level 2 . With the exception of a recently introduced test of a synovial fluid biomarker, namely alpha-defensin, none of the tests being used to diagnose PJI were developed for that purpose, and their optimal threshold for the diagnosis of PJI remains unknown 3 .
Moreover, the ESR and CRP level may be normal in patients with PJI caused by slow-growing organisms such as Propionibacterium acnes 4, 5 . In fact, the document introducing the MSIS criteria for PJI explicitly states that the levels of some of these markers may be normal in the presence of PJI caused by slow-growing organisms that do not elicit physiological inflammation and cautions clinicians in interpreting the levels of serological markers in these situations 6 . Recently, synovial fluid biomarkers have been shown to be useful in reaching or refuting the diagnosis of PJI. The combined measurement of synovial fluid alpha-defensin and CRP for the diagnosis of PJI demonstrated a sensitivity of 97% and a specificity of 100% 7 . There are, however, many issues with the use of synovial biomarkers for the diagnosis of PJI. Obtaining synovial fluid is invasive and painful to patients. There are not infrequent occasions when either an inadequate amount of fluid is available to perform all tests or, worse, no fluid is retrieved from the joint. In addition, there is a theoretical, yet real, concern for the introduction of infection into the joint 8 and, in difficult aspirations, especially in the hip, contamination of the aspirated fluid may occur, leading to false-positive results 9 .
Another challenge relates to the lack of a reliable and easily accessible test that can help to determine the optimal timing of reimplantation. ESR and CRP level are not reliable markers in this situation, as they are often elevated in the postoperative period 10, 11 . Two independent studies demonstrated that the ESR and CRP level at the time of reimplantation are not predictive of treatment failure 12, 13 . The aforementioned issues highlight the need for a reliable serological test that can help to diagnose PJI and possibly determine the optimal timing of reimplantation. We have been in search of such a test over the past few years. Therefore, we have evaluated >30 serological and synovial fluid markers, including D-dimer, for this purpose 1 . Numerous studies have shown that systemic and local infections result in fibrinolytic activities [14] [15] [16] . D-dimer assessment was traditionally used as a screening test for detecting venous thromboembolism (VTE) but was largely abandoned because of its poor accuracy [17] [18] [19] . More recently, The number of included and excluded patients, by group.
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T
assessment of serum D-dimer has gained attention for its role in predicting poor outcome in sepsis and bacteremia 20, 21 . An in vivo study of foals with septic arthritis also demonstrated a marked elevation in the level of synovial fluid D-dimer in these animals 15 . We hypothesized that patients with PJI may have a high level of circulating D-dimer, and that the presence of a high level of D-dimer may be indicative of persistent infection in patients awaiting reimplantation.
Materials and Methods

T
his study received institutional review board approval. From April 2015 to August 2016, we prospectively enrolled patients who were undergoing primary total joint arthroplasty (TJA) or revision arthroplasty. Excluded were patients with any type of skin ulcer, hematoma, a history of recent trauma or dislocation (within 2 weeks), visible ecchymosis, a prosthetic heart valve, or a history of hypercoagulation disorder. A separate group of patients who did not undergo TJA and had infection in a site other than a joint were also enrolled. Patients enrolled in this study were grouped as follows: those undergoing primary TJA (group A), those undergoing revision arthroplasty due to aseptic failure (group B), those undergoing resection arthroplasty and spacer insertion for the treatment of PJI (group C), those with treated PJI undergoing reimplantation surgery (group D), and finally, patients with known infection in a site other than a joint (group E). None of the patients in groups A through D were thought to have concurrent infections.
We recorded patient sex and age, the involved joint, and comorbid conditions including systemic inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, polymyalgia rheumatica, sarcoidosis, inflammatory bowel disease, gout, hepatitis B and C, lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. Moreover, concurrent antibiotic treatment (excluding a single dose of prophylactic perioperative antibiotic) and isolated organisms were noted for all of the patients. A venous blood sample was obtained preoperatively on the day of surgery and analyzed for serum D-dimer, ESR, and CRP. PJI was defined using the MSIS criteria 3 ( Table I ). As part of the standard protocol at our institution, surgeons obtained at least 3 intraoperative tissue culture specimens from patients undergoing revision arthroplasty. Cultures were then incubated for up to 14 days. Furthermore, when a preoperative synovial fluid 1421
aspiration was performed, the WBC count, neutrophil differential, and cultures were requested. Our cohort consisted of 245 patients: 23 in Group A (primary arthroplasty), 86 in group B (aseptic revision), 57 in group C (revision for PJI), 29 in group D (reimplantation), and 50 in group E (clinical diagnosis of infection in a site other than a joint), including 36 cases of urinary tract infection, 9 cases of pneumonia, and 5 cases of upper-respiratory infection. We excluded 11 patients because of a history of trauma within 14 days of the surgery (3 patients), revision for dislocation (3 patients), the presence of extensive ecchymosis (2 patients), the presence of a prosthetic cardiac valve (1 patient), a history of DVT (1 patient), and the presence of a skin ulcer on the hand (1 patient) (Fig. 1) . Patient demographics are presented in Table II .
Patients were followed closely for a minimum of 6 months, and the nature of complications and the reason for any readmission or reoperation was recorded.
Statistical Analysis
Descriptive statistics were used to report all of the laboratory values. The results of the diagnostic tests were compared between the groups using a MannWhitney test, with a p value of <0.005 considered significant. The optimal threshold for D-dimer as diagnostic of PJI was determined by the Youden J statistic (J = sensitivity 1 specificity -1) based on its correspondence with the diagnosis of PJI. The sensitivity and specificity of the diagnostic tests were calculated along with their 95% confidence intervals (CIs). All statistical analyses were performed using GraphPad Prism (version 7.0a; GraphPad Software).
Results
T he serum D-dimer level was significantly higher in the patients with PJI; the median D-dimer level was 1,110 ng/mL (range, 243 to 8,487 ng/mL) in the revision for PJI group compared with 299 ng/mL (range, 106 to 2,571 ng/mL) in the aseptic revision group (p < 0.0001). The mean D-dimer level was 212.5 ng/mL (range, 150 to 430 ng/mL) in the primary arthroplasty cohort, 399.9 ng/mL (range, 106 to 2,571 ng/mL) in the aseptic revision arthroplasty cohort, 1,634 ng/mL (range, 243 to 8,487 ng/mL) in the revision for PJI group, 806.7 ng/mL (range, 170 to 6,381 ng/mL) in the reimplantation group, and 451 ng/mL (range, 150 to 1,420 ng/mL) among the patients with infection in a site other than a joint (Fig. 2) .
The median ESR and CRP values were also significantly higher among the patients with PJI; the median ESR was 46 mm/hr (range, 7 to 127 mm/hr) in the revision for PJI group (group C) compared with 15 mm/hr (range, 2 to 89 mm/hr) in (Fig. 4) (Table III) .
Using the MSIS threshold values indicating the presence of PJI (Table I ), assessments of serum CRP level and ESR demonstrated a sensitivity of 79% (95% CI, 66% to 88%) and 73% (95% CI, 60% to 84%) and a specificity of 80% (95% CI, 72% to 86%) and 78% (95% CI, 70% to 85%), respectively. The sensitivity and specificity of ESR and CRP combined was 84% (95% CI, 76% to 90%) and 47% (95% CI, 36% to 58%), respectively. Using the calculated threshold for D-dimer (850 ng/mL), the serum D-dimer test demonstrated better sensitivity, 89% (95% CI, 77% to 95%), and better specificity, 93% (95% CI, 86% to 96%), for diagnosing PJI (Table IV) . D-dimer was also useful in predicting the presence of infection at the time of reimplantation. Five patients had elevated D-dimer levels at the time of reimplantation (Fig. 2) . Of these patients who underwent reimplantation, 2 had a positive culture from intraoperative specimens (Staphylococcus epidermidis in 1 patient and P. acnes in the other patient [Patients 9 and 14 in Table V] ). Both of these patients subsequently experienced failure due to infection. It is interesting to note that the corresponding CRP and ESR values were falsely negative in both of these patients (a CRP level of 8 mg/L and an ESR of 20 mm/hr for Patient 9 and a CRP level of 1 mg/L and an ESR of 9 mm/hr for Patient 14) . We are closely following the other 3 patients with "false positive" D-dimer values at the time of reimplantation.
Seventeen patients in our cohort required reoperations (Table V) . Sixteen patients underwent revision for PJI, of whom 10 patients subsequently underwent reimplantation.
Among these 10 patients, D-dimer had decreased below the threshold level in 6 patients at the time of reimplantation.
The culture results of patients with PJI are provided in Table  VI . The rate of negative cultures for PJI in the cohort was 33% (19 of 57). The false-negative rate for D-dimer in this subgroup was 11% (2 of 19), whereas it was 47% (9 of 19) for CRP and 53% (10 of 19) for ESR (Table VII) . The data relating to patients with infection in a site other than a joint were very interesting. All 50 (100%) of the patients had an elevated ESR (>30 mm/hr), 42 (84%) of the patients had an elevated CRP level (>10 mg/L), and the D-dimer level was elevated (>850 ng/dL) in 6 (12%) of the patients.
Discussion
T his is, to our knowledge, the first study to evaluate the role of serum D-dimer assessment as a diagnostic test for PJI and for predicting the presence of infection in patients awaiting reimplantation. In our cohort, D-dimer was more accurate than were ESR and CRP, even when combined, in diagnosing PJI and also in predicting the presence of infection at the time of reimplantation. Of 5 patients with "elevated" D-dimer at the time of reimplantation, 2 patients had a positive culture from the samples taken during reimplantation. ESR and CRP values were both normal in these 2 patients. Both of these patients subsequently experienced failure due to infection. Thus, we believe that the sensitivity and specificity of D-dimer is likely higher than calculated in this cohort, as some of the patients with "positive" D-dimer results who were classified as noninfected may indeed have had infection by slow-growing organisms that *S. aureus = Staphylococcus aureus, MSSA = methicillin-sensitive S. aureus, S. epidermidis = Staphylococcus epidermidis, NA = not available, P. acnes = Propionibacterium acnes, S. sanguinis = Streptococcus sanguinis, MRSA = methicillin-resistant S. aureus, and S. marcescens = Serratia marcescens.
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did not elicit physiological inflammation and failed to meet the MSIS criteria for PJI. The MSIS workgroup proposing the PJI definition cautioned clinicians about such a possibility, when organisms such as P. acnes causing PJI may not elicit adequate inflammation and all minor criteria may be negative 22, 23 . Thus, using the MSIS criteria for these patients may have adversely affected the apparent performance of the D-dimer test.
Clinicians are familiar with serum D-dimer assessment, as it has been used, albeit with disappointing performance, in screening patients for venous thromboembolism (VTE) [17] [18] [19] . In recent years, evidence has emerged to suggest that D-dimer levels are likely to rise in the setting of systemic inflammation and infection, especially in a joint 15, 20, 21 . Busso and Hamilton explained how D-dimer levels are elevated in patients with rheumatoid arthritis 24 . Inflamed synovium secrets a large amount of fibrin, and degradation of this protein subsequently leads to an increased concentration of serum and synovial fluid D-dimer 24 . Studies have also shown that coagulation factors that are formed following activation of the coagulation cascade can have proinflammatory effects 25, 26 . Inducible tissue factor expression has been observed in endothelial cells and monocytes following in vitro augmentation with proinflammatory factors, such as cytokines (IL-1, IL-6, and tumor necrosis factor [TNF]) 27 . Furthermore, several studies have shown that fibrinogen (fibrin) itself can mediate and enhance the inflammatory response [28] [29] [30] . Ribera et al. demonstrated that the concentration of synovial fluid D-dimer increased severalfold in foals with septic joint disease 15 , endorsing the belief that D-dimer is involved in mediating inflammation or infection in the joint. The increased fibrinolytic activity and generation of byproducts such as D-dimer are believed to localize the infecting organisms or inflammatory cells and thus prevent them from causing systemic damage. The byproduct of this fibrinolytic activity also "leaks" into the circulation and can thus be measured.
Serum D-dimer has been shown to be a major prognostic factor in patients with systemic sepsis. Rodelo et al. reported that higher levels of D-dimer were associated with increased 28-day mortality in patients with sepsis and emphasized the prognostic role of D-dimer among septic patients 31 . The current study had several strengths. First, patients were recruited prospectively and, unlike most diagnostic studies that limit their population to patients without concurrent inflammatory conditions, our cohort was heterogeneous and included patients with inflammatory conditions, metallosis, and polyethylene wear as well as those who were receiving ongoing antibiotic therapy. We believe that the inclusion of these patients provided a more realistic clinical situation allowing for the evaluation of D-dimer in the clinical setting. As part of our ongoing efforts, our group previously investigated numerous other serum biomarkers in an animal model of PJI and also in a small cohort of patients and found that D-dimer outperformed all of the other serum markers of infection 1 . The second strength of this study is that we included a cohort of "positive control" patients with infection in sites other than a joint. This allowed us to assess whether D-dimer is elevated by non-joint-related infections. It appeared that D-dimer is a better test than ESR and CRP assessment in this clinical setting, as the D-dimer level was 
Staphylococcus epidermidis 9
Methicillin-resistant Staphylococcus aureus 4
Propionibacterium acnes 3
Streptococcus agalactiae group B 2
Polymicrobial 2
Anaerobic gram-positive cocci 1
Klebsiella pneumoniae 1
Streptococcus sanguinis 1
Enterobacter cloacae 1 
Streptococcus mutans 1
Serratia marcescens 1 Negative cultures 19
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elevated in only 12% of patients, compared with ESR, which was elevated in 100%, and CRP, which was elevated in 84% of the patients. The other strength of this study is that we evaluated the role of a serum marker for patients undergoing reimplantation, arguably the most understudied area in orthopaedic infections. D-dimer appeared to have an impressive performance in that setting. Finally, we used statistical methods to determine the appropriate threshold for D-dimer for the diagnosis of PJI. Although this threshold could change with the addition of data from our institution or others, it is a great starting point and a guide to clinicians who may wish to use this test. This study also had some limitations, and our findings should be interpreted in light of those shortcomings. There is no "gold standard" for the diagnosis of PJI, and therefore, some of the patients who were allocated to the aseptic revision group, in fact, might have had PJI. The MSIS criteria for PJI, however, are universally accepted as the best definition for PJI 3 and were used as the gold standard in this study and in the analyses that were performed. Although patients with systemic inflammatory diseases and those who received immunosuppressive therapies were not excluded from this study, our cohort contained only a few patients with these conditions. In the absence of a large number of patients, we refrain from making comments regarding the value of D-dimer assessment for the diagnosis of PJI in patients who have concurrent inflammatory joint disease. We are, in a follow-up study, examining this issue. Lastly, the lack of a frozen section procedure for these patients may be considered a shortcoming. We do not routinely perform frozen section or histological analysis for our patients undergoing revision surgery or reimplantation because we believe such tests, at least at our institution, have serious limitations. Therefore, data related to frozen sections or histology were not available for comparison.
This study, to our knowledge, is the first to demonstrate the real value of serum D-dimer assessment for the diagnosis of PJI and for determining the presence of infection in patients undergoing reimplantation. On the basis of our findings, we believe that serum D-dimer assessment, an inexpensive and universally available test, should be added to the patient workup for PJI. An elevated D-dimer level in patients undergoing reimplantation should be considered seriously, as it could be an indication of persistent infection. n
